Last reviewed · How we verify

NCT03686787

Oral Tranexamic Acid and Laser for Treatment of Melasma

Status unknown Phase 4 Last updated 27 September 2018
What this trial tests

Phase 4 trial testing Tranexamic Acid in Melasma in 32 participants. Status unknown.

Timeline
1 October 2018
Primary endpoint
31 July 2019
1 October 2019

Quick facts

Lead sponsorLaser and Skin Surgery Center of New York
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment32
Start date1 October 2018
Primary completion31 July 2019
Estimated completion1 October 2019
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Laser and Skin Surgery Center of New York

Who can join

Adults 18 to 50, any sex, with Melasma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tranexamic acid and 1927 diode laser non-ablative fractionated laser for the treatment of Melasma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tranexamic Acid

Trials testing the same drug.

Other recruiting trials for Melasma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03686787.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing